TargetMol

Iptakalim Hydrochloride

Product Code:
 
TAR-T27624
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27624-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27624-1mL1 mL * 10 mM (in DMSO)£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27624-10mg10mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27624-25mg25mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27624-50mg50mg£264.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27624-100mg100mg£362.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.
CAS:
642407-63-4
Formula:
C9H22ClN
Molecular Weight:
179.73
Pathway:
Membrane transporter/Ion channel; Neuroscience
Purity:
0.95
SMILES:
Cl.CC(C)NC(C)(C)C(C)C
Target:
Potassium Channel; AChR

References

1. Mengyu He, et al. Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation, migration, and angiogenesis via Akt/eNOS pathways. Pulm Circ. 2019 Oct 18;9(3):2045894019875417. 2. Zhou HM, Zhong ML, Wang RH, Long CL, Zhang YF, Cui WY, Wang H. Synergisms of cardiovascular effects between iptakalim and amlodipine, hydrochlorothiazide or propranolol in anesthetized rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2015 Nov;31(6):532-40. PubMed PMID: 27215021. 3. Wang SY, Cui WY, Wang H. The new antihypertensive drug iptakalim activates ATP-sensitive potassium channels in the endothelium of resistance blood vessels. Acta Pharmacol Sin. 2015 Dec;36(12):1444-50. doi: 10.1038/aps.2015.97. Epub 2015 Nov 23. PubMed PMID: 26592519; PubMed Central PMCID: PMC4816240. 4. Fan Y, Kong H, Ye X, Ding J, Hu G. ATP-sensitive potassium channels: uncovering novel targets for treating depression. Brain Struct Funct. 2016 Jul;221(6):3111-22. doi: 10.1007/s00429-015-1090-z. Epub 2015 Aug 20. PubMed PMID: 26289962.